Cargando…

The hyper-reactive malarial splenomegaly: a systematic review of the literature

BACKGROUND: The hyper-reactive malarial splenomegaly syndrome (HMS) is a leading cause of massive splenomegaly in malaria-endemic countries. HMS is caused by a chronic antigenic stimulation derived from the malaria parasite. Classic Fakunle’s major criteria for case definition are: persistent gross...

Descripción completa

Detalles Bibliográficos
Autores principales: Leoni, Stefania, Buonfrate, Dora, Angheben, Andrea, Gobbi, Federico, Bisoffi, Zeno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438638/
https://www.ncbi.nlm.nih.gov/pubmed/25925423
http://dx.doi.org/10.1186/s12936-015-0694-3
_version_ 1782372372639121408
author Leoni, Stefania
Buonfrate, Dora
Angheben, Andrea
Gobbi, Federico
Bisoffi, Zeno
author_facet Leoni, Stefania
Buonfrate, Dora
Angheben, Andrea
Gobbi, Federico
Bisoffi, Zeno
author_sort Leoni, Stefania
collection PubMed
description BACKGROUND: The hyper-reactive malarial splenomegaly syndrome (HMS) is a leading cause of massive splenomegaly in malaria-endemic countries. HMS is caused by a chronic antigenic stimulation derived from the malaria parasite. Classic Fakunle’s major criteria for case definition are: persistent gross splenomegaly, elevated anti-malarial antibodies, IgM titre >2 SD above the local mean value and favourable response to long-term malaria prophylaxis. The syndrome is fatal if left untreated. The aim of this study is to systematically review the literature about HMS, particularly focussing on case definition, epidemiology and management. METHODS: The search strategy was based on the following database sources: Pubmed, EmBase, Scopus. Search was done in March, 2014 and limited to English, Spanish, Italian, French, and Portuguese. RESULTS: Papers detected were 149, of which 89 were included. Splenomegaly was variably defined and the criterion of increased IgM was not always respected. The highest prevalence was reported in Papua New Guinea (up to 80%). In different African countries, 31 to 76% of all splenomegalies were caused by HMS. Fatality rate reached 36% in three years. The most frequent anti-malarial treatments administered were weekly chloroquine or daily proguanil from a minimum of one month to lifelong. In non-endemic countries, a few authors opted for a single, short anti-malarial treatment. All treated patients with no further exposure improved. Cases not completely fulfilling Fakunle’s criteria and therefore untreated, subsequently evolved into HMS. It seems thus appropriate to treat incomplete or ‘early’ HMS, too. CONCLUSIONS: For patients not re-exposed to endemic areas, a short course of treatment is sufficient, showing that eradicating the infection is sufficient to cure HMS. Longer (probably lifelong) courses, or intermittent treatments, are required for those who remain exposed. Splenectomy, associated with high mortality, should be strictly limited to cases not responding to medical treatment.
format Online
Article
Text
id pubmed-4438638
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44386382015-05-21 The hyper-reactive malarial splenomegaly: a systematic review of the literature Leoni, Stefania Buonfrate, Dora Angheben, Andrea Gobbi, Federico Bisoffi, Zeno Malar J Research BACKGROUND: The hyper-reactive malarial splenomegaly syndrome (HMS) is a leading cause of massive splenomegaly in malaria-endemic countries. HMS is caused by a chronic antigenic stimulation derived from the malaria parasite. Classic Fakunle’s major criteria for case definition are: persistent gross splenomegaly, elevated anti-malarial antibodies, IgM titre >2 SD above the local mean value and favourable response to long-term malaria prophylaxis. The syndrome is fatal if left untreated. The aim of this study is to systematically review the literature about HMS, particularly focussing on case definition, epidemiology and management. METHODS: The search strategy was based on the following database sources: Pubmed, EmBase, Scopus. Search was done in March, 2014 and limited to English, Spanish, Italian, French, and Portuguese. RESULTS: Papers detected were 149, of which 89 were included. Splenomegaly was variably defined and the criterion of increased IgM was not always respected. The highest prevalence was reported in Papua New Guinea (up to 80%). In different African countries, 31 to 76% of all splenomegalies were caused by HMS. Fatality rate reached 36% in three years. The most frequent anti-malarial treatments administered were weekly chloroquine or daily proguanil from a minimum of one month to lifelong. In non-endemic countries, a few authors opted for a single, short anti-malarial treatment. All treated patients with no further exposure improved. Cases not completely fulfilling Fakunle’s criteria and therefore untreated, subsequently evolved into HMS. It seems thus appropriate to treat incomplete or ‘early’ HMS, too. CONCLUSIONS: For patients not re-exposed to endemic areas, a short course of treatment is sufficient, showing that eradicating the infection is sufficient to cure HMS. Longer (probably lifelong) courses, or intermittent treatments, are required for those who remain exposed. Splenectomy, associated with high mortality, should be strictly limited to cases not responding to medical treatment. BioMed Central 2015-04-29 /pmc/articles/PMC4438638/ /pubmed/25925423 http://dx.doi.org/10.1186/s12936-015-0694-3 Text en © Leoni et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Leoni, Stefania
Buonfrate, Dora
Angheben, Andrea
Gobbi, Federico
Bisoffi, Zeno
The hyper-reactive malarial splenomegaly: a systematic review of the literature
title The hyper-reactive malarial splenomegaly: a systematic review of the literature
title_full The hyper-reactive malarial splenomegaly: a systematic review of the literature
title_fullStr The hyper-reactive malarial splenomegaly: a systematic review of the literature
title_full_unstemmed The hyper-reactive malarial splenomegaly: a systematic review of the literature
title_short The hyper-reactive malarial splenomegaly: a systematic review of the literature
title_sort hyper-reactive malarial splenomegaly: a systematic review of the literature
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438638/
https://www.ncbi.nlm.nih.gov/pubmed/25925423
http://dx.doi.org/10.1186/s12936-015-0694-3
work_keys_str_mv AT leonistefania thehyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT buonfratedora thehyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT anghebenandrea thehyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT gobbifederico thehyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT bisoffizeno thehyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT leonistefania hyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT buonfratedora hyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT anghebenandrea hyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT gobbifederico hyperreactivemalarialsplenomegalyasystematicreviewoftheliterature
AT bisoffizeno hyperreactivemalarialsplenomegalyasystematicreviewoftheliterature